enGene Therapeutics reported total assets of $288.32M and total liabilities of $58.03M for the quarter ended Jul 2026, up 17.4% year over year. This balance sheet covers 16 quarters of results from Oct 2022 through Jul 2026, standardized by Business Quant from the company’s SEC filings.
| Balance Sheet | Oct2022 | Jan2023 | Apr2023 | Jul2023 | Oct2023 | Jan2024 | Apr2024 | Jul2024 | Oct2024 | Jan2025 | Apr2025 | Jul2025 | Oct2025 | Jan2026 | Apr2026 | Jul2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Accumulated Depreciation | 1.55M | 1.73M | 1.81M | 1.89M | 1.53M | 1.61M | 1.71M | 1.82M | 1.93M | 2.10M | 2.29M | 2.46M | 2.63M | |||
| Assets | ||||||||||||||||
| Current Assets | ||||||||||||||||
| Cash & EquivalentsCash & Equiv. | 20.43M | 81.52M | 85.65M | 264.81M | 257.68M | 173.00M | 62.35M | 57.55M | 32.62M | 50.15M | 36.61M | 29.83M | 41.02M | |||
| Prepaid Assets | 0.74M | 1.50M | 2.72M | 3.51M | 4.70M | 8.63M | 8.00M | 9.98M | 8.62M | 6.65M | 12.00M | 10.64M | 10.53M | |||
| Current Assets | 22.58M | 85.44M | 89.58M | 269.61M | 262.69M | 247.36M | 222.32M | 227.97M | 211.31M | 201.39M | 289.22M | 270.00M | 277.90M | |||
| Non-Current Assets | ||||||||||||||||
| Property, Plant & Equipment (Net) | 0.39M | 0.59M | 0.99M | 1.11M | 1.01M | 1.17M | 1.37M | 1.55M | 1.88M | 2.48M | 2.44M | 2.33M | 2.16M | |||
| Long-Term Investments | 59.53M | 58.98M | 34.11M | 23.01M | 8.52M | 36.60M | 26.71M | |||||||||
| Other Non-Current Assets | 0.94M | 0.93M | 0.97M | 0.97M | 1.38M | 1.37M | 1.58M | 1.38M | 1.38M | 1.36M | 1.39M | 1.38M | 1.39M | |||
| Non-Current Assets | 1.33M | 1.52M | 3.84M | 3.92M | 4.18M | 63.81M | 63.61M | 38.68M | 34.24M | 20.08M | 47.90M | 37.52M | 10.42M | |||
| Assets | 23.91M | 86.96M | 93.42M | 273.53M | 266.88M | 311.17M | 285.93M | 266.65M | 245.55M | 221.47M | 337.11M | 307.52M | 288.32M | |||
| Liabilities | ||||||||||||||||
| Current Liabilities | ||||||||||||||||
| Accounts Payables | 0.72M | 1.16M | 1.27M | 0.21M | 2.86M | 1.41M | 2.60M | 1.57M | 2.38M | 6.69M | 2.44M | 1.79M | 2.54M | |||
| Notes Payables | 1.26M | 39.98M | 0.56M | 1.34M | 0.70M | 1.69M | 3.57M | 5.41M | 8.00M | 0.19M | 0.19M | 0.20M | ||||
| Payables | 1.99M | 39.98M | 1.72M | 1.27M | 0.21M | 4.20M | 2.11M | 4.29M | 5.14M | 7.80M | 14.69M | 2.62M | 1.99M | 2.74M | ||
| Accumulated Expenses | 3.12M | 3.54M | 5.24M | 5.67M | 8.83M | 12.13M | 8.24M | 12.43M | 11.12M | 15.28M | 19.67M | 17.21M | 22.22M | |||
| Other Accumulated Expenses | 0.11M | 0.06M | 0.27M | 0.40M | 0.23M | 0.56M | 0.51M | 0.61M | 0.58M | 0.23M | 0.95M | 0.67M | ||||
| Current Taxes | 0.02M | 0.04M | 0.01M | 0.03M | 0.09M | 0.33M | 0.57M | 0.02M | ||||||||
| Total Current Liabilities | 5.10M | 5.26M | 6.91M | 6.30M | 13.46M | 14.66M | 12.96M | 18.00M | 20.44M | 31.98M | 24.61M | 21.48M | 27.21M | |||
| Non-Current Liabilities | ||||||||||||||||
| Non-Current Debt | 9.65M | 9.22M | 22.53M | 22.73M | 21.61M | 22.47M | 21.70M | 20.02M | 17.71M | 15.32M | 24.74M | 24.91M | 25.16M | |||
| Convertible Debt | 17.41M | |||||||||||||||
| Preferred Stock Liabilities | 53.12M | 53.12M | 53.12M | |||||||||||||
| Operating Leases | 1.60M | 1.53M | 1.48M | 1.43M | 1.33M | 1.34M | 6.73M | 6.46M | 6.22M | 5.96M | 5.67M | |||||
| Other Non-Current Liabilities | 11.46M | |||||||||||||||
| Total Non-Current Liabilities | 89.07M | |||||||||||||||
| Total Liabilities | 100.52M | 14.47M | 31.04M | 30.56M | 36.55M | 38.56M | 35.98M | 39.36M | 44.88M | 53.76M | 55.57M | 52.36M | 58.03M | |||
| Shareholder's Equity | ||||||||||||||||
| Total Debt | 10.91M | 39.98M | 9.78M | 22.53M | 22.73M | 22.95M | 23.17M | 23.39M | 23.59M | 23.12M | 23.33M | 24.92M | 25.10M | 25.35M | ||
| Common Equity | -76.61M | -84.01M | -89.24M | -93.92M | 72.49M | 62.38M | 242.97M | 230.33M | 272.61M | 249.95M | 227.29M | 200.67M | 167.71M | 281.55M | 255.17M | 230.29M |
| Liabilities and Shareholders Equity | 23.91M | 86.96M | 93.42M | 273.53M | 266.88M | 311.17M | 285.93M | 266.65M | 245.55M | 221.47M | 337.11M | 307.52M | 288.32M | |||
| Retained Earnings | -99.67M | -199.59M | -210.30M | -225.30M | -239.43M | -254.73M | -279.35M | -305.20M | -334.20M | -372.03M | -401.80M | -432.01M | -464.51M |
Pull enGene Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/statements?ticker=ENGN&statement=BS&frequency=Quarter&period=all&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/statements"
params = {"ticker": "ENGN", "statement": "BS", "frequency": "Quarter", "period": "all", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/statements?ticker=ENGN&statement=BS&frequency=Quarter&period=all&api_key=YOUR_API_KEY");
const data = await res.json();